Malvin Yan, DO
Nephrology · South Gate, CANPI 1033153101
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 242 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,223, 2.5 times the $494 reported in 2019.
Across 242 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$732
- AstraZeneca$409
- Mallinckrodt Hospital Products Inc.$365
- Akebia Therapeutics Inc$359
- Otsuka America Pharmaceutical, Inc.$347
- OPKO Pharmaceuticals, LLC$336
- plus $3K from 25 others
Across 873 payments — averaging $3732.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$1.2M
- Astrazeneca UK Limited$882K
- AstraZeneca$695K
- Alnylam Pharmaceuticals Inc.$297K
- Eli Lilly$78K
- Ardelyx, Inc.$46K
- plus $47K from 4 others
What the payments were for
- Food & beverage$4,91497%
- Education$1383%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 46 | $732 |
| AstraZeneca | 18 | $409 |
| Mallinckrodt Hospital Products Inc. | 11 | $365 |
| Akebia Therapeutics Inc | 17 | $359 |
| Otsuka America Pharmaceutical, Inc. | 14 | $347 |
| OPKO Pharmaceuticals, LLC | 29 | $336 |
| Fresenius USA Marketing, Inc. | 18 | $311 |
| GSK | 4 | $208 |
| Novo Nordisk | 10 | $205 |
| Calliditas Therapeutics US Inc. | 7 | $177 |
| Sanofi | 5 | $155 |
| Ardelyx, Inc. | 5 | $146 |
| Pfizer | 2 | $144 |
| Novartis | 6 | $141 |
| Bayer | 6 | $139 |
| Lundbeck LLC | 6 | $138 |
| ANI Pharmaceuticals, Inc. | 4 | $112 |
| E.r. Squibb & Sons, L.L.C. | 6 | $99 |
| Travere Therapeutics, Inc. | 7 | $99 |
| Lilly USA, LLC | 3 | $63 |
| Dexcom, Inc. | 2 | $53 |
| Amarin Pharma, Inc. | 2 | $49 |
| Xeris Pharmaceuticals, Inc. | 2 | $46 |
| Merck | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Boehringer Ingelheim | 1 | $32 |
| Vifor Pharma, Inc. | 2 | $29 |
| Sunovion Pharmaceuticals Inc. | 2 | $26 |
| Lantheus Medical Imaging, Inc. | 1 | $24 |
| Amicus Therapeutics, Inc. | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,052 in reported general payments places this provider in the 75th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 265 | $91,563 |
| JardianceEmpagliflozin | 91 | $72,291 |
| FarxigaDapagliflozin Propanediol | 55 | $58,443 |
| TrulicityDulaglutide | 32 | $41,883 |
| KerendiaFinerenone | 37 | $38,389 |
| XareltoRivaroxaban | 63 | $31,529 |
| JanuviaSitagliptin Phosphate | 61 | $29,656 |
| EntrestoSacubitril/Valsartan | 31 | $29,009 |
| SantylCollagenase Clostridium Hist. | 41 | $27,656 |
| VascepaIcosapent Ethyl | 40 | $27,630 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $27,612 |
| InvokanaCanagliflozin | 25 | $26,119 |
| Sevelamer Hcl | 23 | $25,608 |
| RayaldeeCalcifediol | 21 | $23,957 |
| TradjentaLinagliptin | 20 | $23,143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $32 | $95,435111 claims |
| PfizerEliquis | $144 | $91,563265 claims |
| AstraZenecaFarxiga, Lokelma, Brilinta | $409 | $84,254128 claims |
| Lilly USA, LLCTrulicity | $63 | $41,88332 claims |
| BayerKerendia | $139 | $38,38937 claims |
| Novo NordiskOzempic, Rybelsus | $205 | $31,74332 claims |
| MerckJanuvia | $37 | $29,65661 claims |
| NovartisEntresto | $141 | $29,00931 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $336 | $23,95721 claims |
| GSKTrelegy Ellipta, Arexvy | $208 | $20,44839 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,341 nephrology providers in California.
Other nephrology in South Gate
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
- Suphamai BunnapradistLos Angeles$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.